Volume 2 Issue 1

Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term

Kenneth Blum, Rajendra D. Badgaiyan, Eric R. Braverman, Kristina Dushaj, Mona Li, et al
Unlike other drugs of abuse such as alcohol, nicotine, opiates/opioids, the FDA has not approved any agent to treat psychostimulant dependence. Certainly, it is widely acceptable that dopaminergic signaling is a key factor in both the initiation and continued motivation to abuse this class of stimulant substances.

Read More

KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?

Thomas McLaughlin, Marcelo Febo, Thomas Simpatico, Rajendra D. Badgaiyan, Debmalya Barh, et al.
Major Depressive Disorder (MDD) is a condition that affects approximately 12% of the population [1] and recurs at a rate between 50-85% regardless of treatment [2]. Treatment resistant depression (TRD) is considered if patients
do not show alleviation of depressive symptoms after at least two trials of antidepressants from different pharmacologic classes [3].

Read More